RecruitingNCT06698679

The Association Between Plasma Metabolites and the Risk, Efficacy and Prognosis in Early Breast Cancer

Sponsor

Shengjing Hospital

Enrollment

1,000 participants

Start Date

Nov 15, 2024

Study Type

OBSERVATIONAL

Conditions

Breast Cancer

Summary

This study investigates plasma metabolites to clarify the relationship between these metabolites and breast cancer, aiming to identify valuable biomarkers. Furthermore, by incorporating clinical information-such as cancer stage, type, treatment outcomes, and prognosis-into prospective studies, the research seeks to further examine the correlation between plasma metabolites, treatment efficacy, and prognosis.

Eligibility

Sex: FEMALEMin Age: 18 Years

Inclusion Criteria3

Cohort 1 Control Group: women without breast cancer or other malignancies. Case Group: patients with histologically confirmed carcinoma in situ or invasive breast cancer; no prior treatment; no distant metastasis; and not associated with other malignant tumor diseases.
Cohort 2 Pathologically diagnosed as breast cancer; Treatment niave patients; To receive standard neoadjuvant therapy; Eastern Cooperative Oncology Group (ECOG) performance status of 0-1; Presence of at least one measurable lesion according to the Response Evaluation Criteria in Advanced Solid Tumors version 1.1 (RECIST v1.1) .
Cohort 3 Patients who have been discharged after breast cancer treatment.

Exclusion Criteria1

Histologically undiagnosed breast cancer. Breast cancer with distant metastases. Combined with other malignant tumors. Participants must not have participated in other clinical trials within the past month, unless those trials are observational or non-interventional in nature.

Interventions

OTHERNo intervention

There is no intervention in this study. We will obtain blood from the recruited patients and assess the metabolites therein. This is an observational work.